| DIRECT COMPETITOR COMPARISON | |
| BHRT.OB | ACTC.OB | BAX | Pvt1 | Industry | | Market Cap: | 17.36M | 74.96M | 33.05B | N/A | 100.26M | | Employees: | N/A | N/A | 48,500 | 501 | 65 | | Qtrly Rev Growth (yoy): | -37.20% | 39.30% | -0.20% | N/A | 19.70% | | Revenue (ttm): | 231.42K | 1.03M | 12.22B | 4.00M1 | 14.05M | | Gross Margin (ttm): | 46.54% | 34.56% | 51.23% | N/A | 65.67% | | EBITDA (ttm): | -5.96M | -5.49M | 3.37B | N/A | -12.30M | | Oper Margins (ttm): | -2,651.86% | -576.97% | 22.54% | N/A | -137.11% | | Net Income (ttm): | -8.38M | -67.23M | 2.20B | N/A | N/A | | EPS (ttm): | -0.496 | -0.160 | 3.562 | N/A | -0.32 | | P/E (ttm): | N/A | N/A | 15.39 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | 1.25 | N/A | 1.31 | | P/S (ttm): | 75.03 | 73.10 | 2.70 | N/A | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BAX | | 10 Dividend Picks For Your Portfolio: Chief Investors
Wed, Nov 25 -
at CNBC | | • | BAX | | [video] The Dividend Strategy
Wed, Nov 25 -
at CNBC | | • | ACTC.OB | | ADVANCED CELL TECHNOLOGY, INC. Financials
Tue, Nov 24 -
EDGAR Online Financials | | • | ACTC.OB | | Advanced Cell Technology to Present at LD Micro Conference in Los Angeles
Tue, Nov 24 -
Business Wire | | • | BAX | | Becton Acquires HandyLab
Mon, Nov 23 -
Zacks.com | | • | BAX | | 30 High Yielding Option Write Ideas for November Option Expiration Friday
Fri, Nov 20 -
at Seeking Alpha | | • | BAX | | Healthcare Spin Off Companies Offer Opportunity To Investors According To Credit Suisse Senior Analyst
Thu, Nov 19 -
Wall Street Transcript | | • | ACTC.OB | | RPT-Company seeks to test stem cells for blindness
Thu, Nov 19 -
at Reuters | | • | ACTC.OB | | Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
Thu, Nov 19 -
Business Wire | | • | BAX | | Sector Snap: UBS upbeat on medical tech stocks
Wed, Nov 18 -
AP | | • | BAX | | Coverage initiated on Baxter by Morgan Keegan
Wed, Nov 18 -
Briefing.com | | • | ACTC.OB | | ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
Tue, Nov 17 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
